Page 5 - genveon oznur

82 L. Elmer et al. / Journal of the Neurological Sciences 248 (2006) 78–83

necticut, Hartford; Neal Hermanowicz, MD, Shari Nis- with Parkinson’s disease on levodopa. J Neurol Neurosurg Psychiatry
wonger, RN: University of California, Irvine; Mandar Jog, 1980;43:1016–21.
[10] Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of
MD PhD; Cheryl Horn, RN: London Health Sciences
daily fluctuations in disability of Parkinsonian patients with long-term
Center, Ontario; Lisa Shulman, MD, Michelle Cines, RN: levodopa treatment. Acta Neurol Scand 1989;80(Suppl. 126):113–8.
University of Maryland School of Medicine, Baltimore; [11] Golbe LI, Lieberman AN, Muenter MD, Ahlskog JE, Gopinathan G,
Oksana Suchowersky, MD, Sarah Furtado MD PhD, Lorelei Neophytides AN, et al. Deprenyl in the treatment of symptom
Derwent, RN: University of Calgary, Calgary; Johan fluctuation in advanced Parkinson’s disease. Clin Neuropharmacol
1988;11:45–55.
Samanta, MD: Barrow Neurological Institute, Phoenix;
[12] Ulm G, Fornadi F. R-( )-deprenyl in the treatment of end-of-dose
Carmen Serrano Ramos, MD, Laritza Berrios, RN: Univer- akinesia. J Neural Transm Suppl 1987;25:163–72.
sity of Puerto Rico School of Medicine, San Juan; James [13] Hubble JP, Koller WC, Waters C. Effect of selegiline dosing on motor
Sutton, MD: California Medical Center for Movement fluctuations in Parkinson’s disease. Clin Neuropharmacol 1993;16:83–7.
Disorders, Oxnard; Cheryl Waters: Columbia University [14] Clarke CE, Deane KHO. Ropinirole for levodopa-induced complica-
tions in Parkinson’s disease. Cochrane Database Syst Rev(1).
Medical Center, New York; Carlos Singer, MD: University
doi:10.1002/14651858.CD001516. [Art. No.: CD001516].
___________
___________
_____
of Miami, Miami; Kapil Sethi, MD: Medical College of [15] Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced
Georgia, Augusta; Jayaraman Rao, MD, Maureen Cook, complications in Parkinson’s disease. Cochrane Database Syst Rev(2).
___________
RN, BSN: Louisiana State University Medical Center, New doi:10.1002/14651858.CD002261. [Art. No.: CD002261].
___________
_____
Orleans; Andrew Feigin, MD, Margaret Cox, RN: North [16] Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and
pharmacodynamic properties of drugs used in the treatment of
Shore – LIJ Health System, Manhasset; David Riley, MD:
Parkinson’s disease. Clin Pharmacokinet 2002;41(4):261–309.
University Hospitals of Cleveland, Ohio; Vincent Calabrese, [17] Etminan M, Gill S, Samii A. Comparison of the risk of adverse events
MD, Peggy Roberge, RN: Hunter Homes McGuire Veterans with pramipexole and ropinirole in patients with Parkinson’s disease: a
Medical Center, Richmond; David Standaert, MD, PhD, meta-analysis. Drug Safety 2003;26(6):439–44.
Marsha Tennis, RN: Massachusetts General Hospital, [18] Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of
somnolence with the new dopamine agonists in patients with
Boston; Bala Manyam, MD, Brian Wulbrecht, BA, CCRP:
Parkinson’s disease: a meta-analysis of randomised controlled trials.
Scott & White Hospital/Texas A&M University, Temple; Drug Safety 2001;24(11):863–8.
Alexander Rajput, MD: Saskatoon District Health Board [19] Holm KJ, Spencer CM. Entacapone. A review of its use in Parkinson’s
Royal University Hospital, Saskatoon; Lawrence Golbe, disease. Drugs 1999 (Jul.);58(1):159–77.
MD, Debbie Caputo, RN, MSN: University of Medicine and [20] Inzelberg R, Carasso RL, Schechtman E, Nisipeanu P. A comparison
of dopamine agonists and catechol-O-methyltransferase inhibitors in
Dentistry, New Brunswick, New Jersey; Alan Freeman,
Parkinson’s disease. Clin Neuropharmacol 2000 (Sep.–Oct.);23(5):
MD, Linda McGinn: Emory University School of Medicine, 262–6.
Atlanta; Thyagarajan Subramanian, MD: Cleveland Clinic, [21] Brooks DJ. A placebo-controlled evaluation of ropinirole, a novel D2
Ohio; Todd Ajax, MD: McFarland Neurosciences, Ames; agonist, as sole dopaminergic therapy in Parkinson’s disease. Clin
Michael Aminoff, MD FRCP: University of California, Neuropharmacol 1998 (Mar.–Apr.);21(2):101–7.
[22] Adler CHthe Ropinirole Study Group. Ropinirole for the treatment of
San Francisco.
early Parkinson’s disease. Neurology 1997 (Aug.);49(2):393–9.
[23] Parkinson Study Group. Safety and efficacy of pramipexole in early
Parkinson disease. A randomized dose-ranging study. JAMA 1997
(Jul. 9);278(2):125–30.
References [24] Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C,
et al. Pramipexole in patients with early Parkinson’s disease. Clin
[1] Parkinson Study Group. A controlled trial of rasagiline in early Neuropharmacol 1995 (Aug.);18(4):338–47.
Parkinson’s Disease (The TEMPO Study). Arch Neurol 2002;59: [25] Rascol O. Ropinirole in the treatment of levodopa-induced motor
1937–43. fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol
[2] Parkinson Study Group. A randomized placebo controlled trial of 1996 (Jun.);19(3):234–45.
rasagiline in levodopa-treated Parkinson’s disease patients with motor [26] Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipex-
fluctuations (The PRESTO Study). Arch Neurol 2005;62:241–8. ole in advanced Parkinson’s disease: results of a double-blind,
[3] Jankovic J. New and emerging therapies for Parkinson disease. Arch placebo-controlled, parallel-group study. Neurology 1997 (Jul.);49
Neurol 1999;56:785–90. (1):162–8.
[4] Korczyn AD, Nussbaum M. Emerging therapies in the pharmacolog- [27] Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S,
ical treatment of Parkinson’s disease. Drugs 2002;62:775–86. et al. A multicenter trial of ropinirole as adjunct treatment for
[5] Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis Parkinson’s disease. Neurology 1998;51:1057–62.
and management of Parkinson’s disease. CMAJ 2003;168(3):293–301. [28] Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of
[6] Shults CW. Treatments of Parkinson disease: Circa 2003. Arch Neurol the non-ergoline dopamine agonist pramipexole in the treatment of
2003;60:1680–4; advanced Parkinson’s disease: a double blind, placebo controlled,
Tanner C. Dopamine agonists in early therapy for Parkinson’s disease: randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999;
promise and problems. JAMA 2000;284:1971–93. 66:436–41.
[7] Tanner C. Dopamine agonists in early therapy for Parkinson’s disease: [29] Wermuth LThe Danish Pramipexole Study Group. A double-blind,
promise and problems. JAMA 2000;284:1971–93. placebo-controlled, randomized, multi-center study of pramipexole in
[8] Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, advanced Parkinson’s disease. Eur J Neurol 1998;5:235–42.
Youdim MB. Deprenyl in Parkinson’s disease. Lancet 1977;2:791–5. [30] Parkinson Study Group. Entacapone improves motor fluctuations in
[9] Schachter M, Marsden CD, Parkes JD, Jenner P, Testa B. levodopa-treated Parkinson’s disease patients. Ann Neurol 1997
Deprenyl in the management of response fluctuations in patients (Nov.);42:747–55.